Haemophilia Trial, Recruiting NCT04131036 Sponsor: Washington Institute for Coagulation Condition: Haemophilia
Back to Haemophilia

Haemophilia Trial, Recruiting

NCT04131036
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are male
  • You have severe hemophilia A, meaning your Factor VIII levels are below 1%
  • You are 16 years old or older
  • You are currently taking either Factor VIII or emicizumab as a regular preventive treatment, and you plan to stay on that same treatment for the next 3 years
  • You are willing and able to sign a consent form agreeing to take part
  • You are willing to have joint ultrasound scans, a bone density scan (DEXA), and possibly give blood samples for research purposes
  • You are willing to attend an initial visit and then 3 follow-up visits over 3 years
  • You are willing to answer a phone survey about bleeding and safety every 3 months

Who may not be able to join:

  • You have developed antibodies (called inhibitors) against Factor VIII above a certain level (confirm with trial site)
  • You are unable to receive Factor VIII replacement therapy
  • You have another bleeding disorder in addition to hemophilia A
  • You have a rheumatological condition (such as arthritis) that affects your joints
  • You have a known condition affecting your nerves or movement that would make a physical examination difficult (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rebecca Kruse-Jarres, MD, MPH, Washington Institute for Coagulation

Phone: 206-614-1200

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Washington Institute for Coagulation
Registry
ClinicalTrials.gov
Start date
4 April 2019
Est. completion
1 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

joint health comparison

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov